Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
AVIR - Atea Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$8.50
DETAILS
HIGH:
$10.00
LOW:
$7.00
MEDIAN:
$8.50
CONSENSUS:
$8.50
UPSIDE:
58.38%
Stock News
Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No Approved Therapies Study Initiation Represents an Important Milestone Advancing Atea's Antiviral Pipeline Focusing on First- or Best-in-Class Product Candidates in Areas of High Unmet Medical Need BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection. AT-587 is a proprietary oral antiviral nucleotide analog being developed for the treatment of HEV, a potentially serious liver disease that can lead to chronic infection, cirrhosis and liver failure in certain patient populations.
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) infection. The anticipated topline results from C-BEYOND, the Phase 3 trial conducted in the US and Canada, remain on track for mid-year 2026.
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR's $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie.
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin.
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options.
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “With two pivotal Phase 3 readouts for our HCV program on the horizon, 2026 will be a catalyst-rich year for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update.
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Analyst Ratings This is a breakdown of
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its fourth quarter and full-year 2025 financial results conference call. Management also discussed commercial launch preparations for HCV and reviewed the company's year-end cash position and spending outlook.
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Price Targets
Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley
$7.00
(was $5.06)
Morgan Stanley
Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
$10.00
(was $6.15)
Evercore ISI
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) to Equalweight, 'HCV opportunity comes into focus, while COVID outcome remains uncertain'
$6.88
(was $3.35)
Matthew Harrison
·
Morgan Stanley